Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review

A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira
{"title":"Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review","authors":"A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira","doi":"10.18231/j.jpbs.2023.004","DOIUrl":null,"url":null,"abstract":"Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"144 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research journal of pharmaceutical, biological and chemical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.jpbs.2023.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
他他多,一种阿片类药物作为治疗慢性疼痛的策略?叙述性回顾
慢性疼痛影响着大约30%的世界人口。他他多可作为对常用阿片类药物反应不充分的患者的一种镇痛选择。本研究综述了他他多疼痛治疗的一般方面及其与氧化应激增加的可能关联,以及其与抗氧化物质关联的益处。搜索在Medline (Pubmed)、Scopus、Web of Science和Google学术数据库中进行,包括自2008年该药注册以来的研究。所选的文章是关于使用他他多治疗成人和老年人慢性中重度疼痛,而非癌症相关疼痛的文章。他他多是一种微阿片受体激动剂,可抑制去甲肾上腺素的再摄取。虽然他他多的不良反应比其他传统阿片类药物少,但研究表明他他多可诱导氧化应激,但尚未阐明其机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers Drug repurposing: A futuristic approach in drug discovery A review on ebola virus Evaluation and clinical management of drug-drug interactions in hypertensive patients associated co-morbidities: A study in general medicine and ICU ward Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1